- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01291134
PureGen: Radiographic Analysis of Fusion for ACDF
PureGen Osteoprogenitor Cell Allograft: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multi-center, post-market, observational study assessing subjects undergoing cervical interbody fusion surgery to treat cervical degenerative disc disease (DDD)
Patients diagnosed with cervical degenerative disc disease will be screened for enrollment based on inclusion and exclusion criteria outlined in this protocol. Subjects who are successfully screened and sign an informed consent will undergo ACDF surgery utilizing PureGen, Alphagraft ProFuse Demineralized Bone Scaffold (DBS), a radiolucent cervical interbody spacer, and Trestle or Reveal Anterior Cervical Plating System (plate and screw fixation system).
Subjects will be followed at 6- weeks, 3-, 6-, and 12-month post-operative visits. Standard radiographs will be taken at these visits to assess fusion rate and quality. SF-12, NDI and VAS self assessment questionnaires and neurological exams will be administered to measure pain and function scores. A computerized tomography scan will be taken at the 6 month post operative exam to further assess rate and quality of fusion. A conditional 12-month post operative CT may also be taken. Procedure related and device related adverse events will be monitored throughout the study.
Outcome data will be compared to published and/or retrospective data for the standard of care for DDD patients undergoing ACDF.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Carlsbad, California, United States, 92008
- Alphatec Spine Inc.
-
-
Connecticut
-
Middletown, Connecticut, United States, 06457
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27401
-
Raleigh, North Carolina, United States, 27607
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Persistent neck and/or arm pain consistent to symptomatic cervical degenerative disc disease
- Moderate Neck Disability Index
- Unresponsive to conservative treatment for at least 6 weeks
Exclusion Criteria:
- More than 4 levels requiring surgical treatment
- Prior failed fusion surgery at the index level(s)
- Systemic or local infection in the disc or cervical spine, past or present
- Active systemic disease
- Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing
- Known or suspected history of alcohol and/or drug abuse
- Involved in pending litigation or worker's compensation relating to the spine
- Pregnant or plans to become pregnant during the duration of the study
- Insulin-dependent diabetes mellitus
- Life expectancy less than study duration
- Any significant psychological disturbance that in the opinion of the Investigator could impair consent process or ability to complete self-assessment questionnaires
- BMI greater than 40
- Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs
- Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cervical Degenerative Disc Disease
Subjects suffering from symptoms of cervical degenerative disc disease in one to four contiguous levels between C3 and T1.
|
PureGen Osteoprogenitor Cell Allograft.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fusion
Time Frame: 12 months
|
Proportion of subjects with fusion at the 12-month visit
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bita P. Ghadimi, Alphatec Spine, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-000053
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Degenerative Disc Disease
-
Medtronic Spinal and BiologicsCompletedDegenerative Cervical Disc DiseaseSaudi Arabia, Greece, Serbia, Hungary, Czech Republic, Kuwait, Poland, Slovakia
-
Assiut UniversityNot yet recruiting
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
-
Medtronic Spinal and BiologicsCompletedCervical Degenerative Disc DiseaseUnited States
-
NuVasiveCompletedCervical Degenerative Disc DiseaseUnited States
-
Synergy Spine SolutionsMCRAActive, not recruitingCervical Degenerative Disc DiseaseUnited States
Clinical Trials on PureGen Osteoprogenitor Cell Allograft
-
Alphatec Spine, Inc.TerminatedLumbar Degenerative Disc DiseaseUnited States
-
Alphatec Spine, Inc.TerminatedLumbar Degenerative Disc DiseaseUnited States
-
Baxter Healthcare CorporationApatech, Inc.TerminatedDegenerative Disc Disease | Spinal Stenosis | Herniated Disc | Cervical Myelopathy | Spinal Cord Neoplasms | Spinal Deformity | Failed Back Surgery Syndrome | SpondylolithesisUnited States, Hungary, Netherlands
-
Charite University, Berlin, GermanyActive, not recruitingKidney Transplant Rejection | Antibody-mediated Rejection | Kidney Transplant FailureGermany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyeloproliferative Disorders | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterTerminatedHodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)United States
-
Centre Henri BecquerelUnknownLymphoblastic LymphomaBelgium, France